AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Glenmark Pharma shares surged by 10% to hit the upper circuit level in early trade, reaching Rs 2094.40. This significant ...

Shares of Glenmark gained 10% to Rs 2,094 on July 11, making it a top gainer on the Nifty Midcap 150 index. Mankind Pharma, NMDC, Gland, and Alkem Lab were also among the top gainers. Moneycontrol ...

According to A.I. Stock Analysis, Roku has earned an overall score of 75 out of 100. The stock’s score and upgraded rating are supported by an upbeat earnings call sentiment and favorable technical ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over 375 clinical trials. See why ABBV stock is a Buy.

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.

In Friday’s market session, top Indian corporates like Tata Consultancy Services (TCS), Hindustan Unilever Ltd (HUL), Bharat Forge, and Glenmark Pharma found themselves in focus as global brokerages ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

ASX health stocks fall o.92% over past five days as US President Donald Trump renews threat to impose tariffs on pharmaceutical imports.